Skip to main content
. Author manuscript; available in PMC: 2013 Dec 21.
Published in final edited form as: Cell. 2012 Dec 13;151(7):1457–1473. doi: 10.1016/j.cell.2012.11.026

Figure 4. BCL2L1 and BIRC5 are transcriptional targets of the β-catenin-YAP1-TBX5 complex.

Figure 4

(A) Proliferation or (B) AI growth following suppression of BCL2L1 or BIRC5 in the indicated cell lines. (C, D) mRNA levels of BCL2L1 and BIRC5 in HT55 or HCT116 cells expressing β-catenin-specific, YAP1-specific or control shRNAs. (E) β-catenin, YAP1 or control immune complexes were isolated from HuTu80 cells and subjected to ChIP analysis with primers derived from the promoter regions of BCL2L1 (1-1000 bp) and BIRC5 (−952-0 bp). (F) β-catenin or (G) YAP1 immune complexes were derived from HuTu80 cells expressing TBX5-specific shRNAs were subjected to ChIP analysis using primers for BIRC5. (H) mRNA levels of BCL2L1 and BIRC5 in HCT116 cells expressing TBX⍰-specific shRNAs. (I) Immunoblot analysis of BCL-XL or BIRC5 in HuTu80 cells overexpressing BCL-XL, BIRC5 or LacZ and YAP1-specific, β-catenin-specific or control shRNAs. (J) Proliferation of the cell lines described in (I). Data presented as mean ± SD for 3 independent experiments. See also Figure S4.